Aura Biosciences, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of common stock at a public offering price of $9.00 per share, resulting in net proceeds of approximately $92.6 million. The company intends to use the proceeds for clinical development and general corporate purposes.